Literature DB >> 1899135

The significance of bleeding patterns in Norplant implant users.

D Shoupe1, D R Mishell, B L Bopp, M Fielding.   

Abstract

The purpose of this study was to examine the bleeding patterns of 234 Norplant users during 5 years of use and to identify the bleeding patterns of users who conceived. During the first year of use, 26.6% of users had regular bleeding cycles, 66.3% had irregular cycles, and 7.1% were amenorrheic. By the fifth year of use, 62.5% of users had regular cycles, 37.5% had irregular cycles, and none had amenorrhea. Of the ten users who became pregnant, eight had regular menstrual cycles in the 6 months before the diagnosis of pregnancy, one had an irregular pattern, and one did not keep a bleeding record. None had amenorrhea. The 5-years cumulative pregnancy rate for patients with regular cycles was 17.4%; this was significantly higher (P less than .05) than the 5-year cumulative rates of 4.4% in users with irregular cycles and 0% in users with amenorrhea. This study indicates that during the first year of Norplant use, only 26.6% of users have regular cycles, but after the first year, 50-60% of users develop regular cycles. The bleeding patterns of women using Norplant improve after the first year of use, and those with regular cycles are at greatest risk for method failure.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1899135     DOI: 10.1097/00006250-199102000-00018

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

1.  Factors associated with elective Norplant removal in black and white women.

Authors:  J U Opara; F A Ernst; H Gaskin; L Smith; H V Nevels
Journal:  J Natl Med Assoc       Date:  1997-04       Impact factor: 1.798

2.  Progesterone receptor in the vascular endothelium triggers physiological uterine permeability preimplantation.

Authors:  Lauren M Goddard; Thomas J Murphy; Tönis Org; Josephine M Enciso; Minako K Hashimoto-Partyka; Carmen M Warren; Courtney K Domigan; Austin I McDonald; Huanhuan He; Lauren A Sanchez; Nancy C Allen; Fabrizio Orsenigo; Lily C Chao; Elisabetta Dejana; Peter Tontonoz; Hanna K A Mikkola; M Luisa Iruela-Arispe
Journal:  Cell       Date:  2014-01-30       Impact factor: 41.582

Review 3.  Levonorgestrel subdermal implants. A review of contraceptive efficacy and acceptability.

Authors:  A J Coukell; J A Balfour
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

4.  Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism.

Authors:  W H Catherino; M H Jeng; V C Jordan
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.